3868 results for «2024»

Filter By

3868 results

Alain G. Cribier

07 Nov 2017

In 2002, Alain Cribier revolutionised the field by introducing transcatheter aortic valve implantation (TAVI) as a complementary technique to surgery. Find out more about his early life and studies.

Alain G. Cribier: Legion of honour

Use of advanced coronary techniques in bailout of aortic valvuloplasty balloon entrapment

25 Mar 2025

Balloon entrapment in valvuloplasty can be life-threatening, especially after balloon rupture. Learn about a new technique involving balloon internalisation and safety snares for successful retrieval and sheath upsizing.

Aortic valvuloplasty balloon entrapment

ViV challenges in degenerated sutureless bioprosthesis

08 Apr 2025

Watch this EuroIntervention image to learn how the collision of a TAV device during valve crossing in ViV TAVI can potentially cause instability or dehiscence of the sutureless bioprosthesis, contributing to severe poorly tolerated PVL.

New challenges during transcatheter aortic valve-in-valve implantation inside a degenerated sutureless bioprosthesis

SMT launches Hydra Transcatheter Aortic Valve Replacement (TAVR) system in Mexico, expanding global reach

20 Dec 2024

FFR or 3d-quantitative coronary angiography-based vessel-FFR guided revascularisation – The FAST III trial

28 Mar 2026

Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.

Author

Chiara De Biase
FAST III: FFR vs 3D-QCA vessel-guided revascularisation

Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial

31 Oct 2025

Nicola Ryan provides her take on the PROMISE trial presented by Rocco Antonio Montone at TCT 2025, in San Francisco.

Nicola Ryan

Author

Nicola Ryan
Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery (PROCTOR)

03 Nov 2025

Kalaivani Mahadevan and Trisha Singh provide their take on the PROCTOR study presented by Ruben de Winter at TCT 2025, in San Francisco.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Trish Singh

Author

Trish Singh
PROCTOR: PCI of native coronary artery vs SVGin patients with prior CABG

DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock

03 Sep 2025

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

Fizzah Choudry

Author

Fizzah Choudry
Kalaivani Mahadevan

Author

Kalaivani Mahadevan
DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock

Challenging aortas: how to perform TAVI after coarctation surgery?

26 Sep 2024

How do you navigate the complexities of performing TAVI on aortas previously treated for coarctation surgery, while ensuring patient safety through meticulous planning and expert precision? Analyse this image to find out more!

Challenging aortas: how to perform TAVI after coarctation surgery?

Bentley buys key suppliers and engages employees in planned IPO

24 Apr 2023

EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI

20 May 2026

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...

EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI

PCR Fellowship Programmes: A new international stepping stone in PCR’s educational universe

19 May 2026

PCR has developed an independent educational framework to facilitate the worldwide training of the next generation of interventional cardiologists in host centres that are renowned for their expertise. This new initiative supports practitioners at all stages of their career – promoting professional growth, geographical mobility and cultural exchange.

PCR Fellowship Programmes: A new international stepping stone in PCR’s educational universe

Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial

09 Apr 2024

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)

Daniele Giacoppo

Author

Daniele Giacoppo
Marco Spagnolo

Author

Marco Spagnolo
IVUS-guided vs angiography-guided PCI in acute coronary syndromes

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.

04 Mar 2024

Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial

07 Apr 2024

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Nicola Ryan

Author

Nicola Ryan

Author

Ali Nazmi Calik
REDUCE-AMI: Long-term beta-blocker treatment after AMI and preserved LVEF

Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)

08 Apr 2024

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Author

Ali Nazmi Calik
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques

lmaging: The eyes of the Heart Team

14 May 2024

More than ever, Heart Team members rely on advanced imaging to guide procedures and aid in decision-making about patient selection and management. Just as imaging plays a prominent role in the cathlab, so it will be central to this year's EuroPCR content, with a track of specially...

lmaging: The eyes of the Heart Team

Transcatheter aortic valve implantation without routine percutaneous coronary intervention: A randomized controlled trial (PRO-TAVI Trial)

29 Mar 2026

Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

Jonathan Curio

Author

Jonathan Curio
TAVI without routine PCI: PRO-TAVI randomized controlled trial
Didn’t find what you were looking for?